Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
With funding from the Ultra-rare Gene-based Therapy Network, scientists at Columbia and the n-Lorem Foundation will create tailor-made gene-based therapies for people with rare forms of ALS.
A study led by Columbia and Cornell researchers finds, surprisingly, that anticoagulants do not prevent recurrent strokes in people with one type of heart condition.
Based on Columbia research, an experimental drug for a rare type of ALS is being tested in a phase 3 clinical trial after a new study found that the drug lowered levels of a toxic protein.
Since 1955, “Merritt’s Neurology,” edited by Columbia neurologists, has been regarded as the standard reference work in the field. James Noble, MD, joins the ranks for the latest edition.
New technology will allow scientists to uncover what happens in the brain during the early stages of Parkinson's disease, which could lead to earlier diagnosis and better therapies for the disease.
Spectacular images of a molecule that shuttles omega-3 fatty acids into the brain may open a doorway for delivering neurological therapeutics to the brain.
Driving data captured by vehicle recording devices can help detect mild cognitive impairment and dementia in older drivers, Columbia researchers have found.
Cells used to study the human blood-brain barrier in the lab aren’t what they seem, a new study has found, throwing nearly a decade’s worth of research into question.
A new Columbia study suggests that malfunctioning endosomes—a central trafficking station inside neurons—are commonly involved in the appearance of Alzheimer’s disease.